Actinium Pharmaceuticals (ATNM) Competitors $1.59 +0.10 (+6.71%) Closing price 04:00 PM EasternExtended Trading$1.59 0.00 (0.00%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ATNM vs. VYGR, TLSA, IMAB, LFVN, ENTA, IPHA, ACOG, DERM, SPRO, and DMACShould you be buying Actinium Pharmaceuticals stock or one of its competitors? The main competitors of Actinium Pharmaceuticals include Voyager Therapeutics (VYGR), Tiziana Life Sciences (TLSA), I-Mab (IMAB), Lifevantage (LFVN), Enanta Pharmaceuticals (ENTA), Innate Pharma (IPHA), Alpha Cognition (ACOG), Journey Medical (DERM), Spero Therapeutics (SPRO), and DiaMedica Therapeutics (DMAC). These companies are all part of the "pharmaceutical products" industry. Actinium Pharmaceuticals vs. Its Competitors Voyager Therapeutics Tiziana Life Sciences I-Mab Lifevantage Enanta Pharmaceuticals Innate Pharma Alpha Cognition Journey Medical Spero Therapeutics DiaMedica Therapeutics Voyager Therapeutics (NASDAQ:VYGR) and Actinium Pharmaceuticals (NYSE:ATNM) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, media sentiment, risk, dividends, analyst recommendations, earnings and profitability. Do analysts recommend VYGR or ATNM? Voyager Therapeutics currently has a consensus target price of $13.39, indicating a potential upside of 309.48%. Actinium Pharmaceuticals has a consensus target price of $4.00, indicating a potential upside of 151.57%. Given Voyager Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Voyager Therapeutics is more favorable than Actinium Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Voyager Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13Actinium Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 Which has better earnings & valuation, VYGR or ATNM? Actinium Pharmaceuticals has lower revenue, but higher earnings than Voyager Therapeutics. Voyager Therapeutics is trading at a lower price-to-earnings ratio than Actinium Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVoyager Therapeutics$66.96M2.70-$65M-$1.46-2.24Actinium PharmaceuticalsN/AN/A-$48.82M-$1.47-1.08 Which has more risk and volatility, VYGR or ATNM? Voyager Therapeutics has a beta of 0.85, meaning that its stock price is 15% less volatile than the S&P 500. Comparatively, Actinium Pharmaceuticals has a beta of -0.32, meaning that its stock price is 132% less volatile than the S&P 500. Does the media refer more to VYGR or ATNM? In the previous week, Voyager Therapeutics had 4 more articles in the media than Actinium Pharmaceuticals. MarketBeat recorded 5 mentions for Voyager Therapeutics and 1 mentions for Actinium Pharmaceuticals. Actinium Pharmaceuticals' average media sentiment score of 1.14 beat Voyager Therapeutics' score of 0.49 indicating that Actinium Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Voyager Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Actinium Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals have more ownership in VYGR or ATNM? 48.0% of Voyager Therapeutics shares are owned by institutional investors. Comparatively, 27.5% of Actinium Pharmaceuticals shares are owned by institutional investors. 4.5% of Voyager Therapeutics shares are owned by insiders. Comparatively, 6.0% of Actinium Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Is VYGR or ATNM more profitable? Actinium Pharmaceuticals has a net margin of 0.00% compared to Voyager Therapeutics' net margin of -126.49%. Voyager Therapeutics' return on equity of -27.36% beat Actinium Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Voyager Therapeutics-126.49% -27.36% -21.06% Actinium Pharmaceuticals N/A -100.85%-47.89% SummaryVoyager Therapeutics beats Actinium Pharmaceuticals on 11 of the 16 factors compared between the two stocks. Get Actinium Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ATNM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ATNM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATNM vs. The Competition Export to ExcelMetricActinium PharmaceuticalsPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$49.60M$752.17M$5.57B$20.65BDividend YieldN/A4.84%4.23%3.65%P/E Ratio-1.141.4328.6127.29Price / SalesN/A25.51411.3153.19Price / CashN/A19.5636.0222.28Price / Book1.216.608.234.60Net Income-$48.82M-$4.53M$3.23B$995.22M7 Day Performance0.63%1.40%-0.01%-0.80%1 Month Performance3.92%1.30%5.60%3.55%1 Year PerformanceN/A3.42%26.54%7.35% Actinium Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATNMActinium Pharmaceuticals2.8013 of 5 stars$1.59+6.7%$4.00+151.6%N/A$49.60MN/A-1.1430Positive NewsGap UpVYGRVoyager Therapeutics3.8967 of 5 stars$3.04-5.0%$13.39+340.5%-65.6%$177.08M$80M-2.08100News CoverageGap UpTLSATiziana Life Sciences1.1746 of 5 stars$1.53+1.3%N/A+82.6%$176.44MN/A0.008IMABI-Mab2.8369 of 5 stars$2.09-2.8%$6.00+187.1%+28.8%$175.57M$3.89M0.00380Gap DownLFVNLifevantage4.3406 of 5 stars$13.59-0.9%$30.50+124.4%+102.6%$172.71M$200.16M19.70260News CoverageENTAEnanta Pharmaceuticals3.9251 of 5 stars$7.65-3.0%$18.00+135.3%-60.2%$168.66M$67.64M-1.69160News CoveragePositive NewsIPHAInnate Pharma2.6049 of 5 stars$1.79-1.6%$11.00+514.5%-16.5%$167.76M$21.77M0.00220Positive NewsACOGAlpha Cognition1.7293 of 5 stars$11.24+7.4%$20.00+77.9%N/A$167.65MN/A-9.37N/APositive NewsDERMJourney Medical2.411 of 5 stars$7.11+0.1%$9.50+33.6%+19.9%$165.40M$56.13M-18.2390SPROSpero Therapeutics3.9001 of 5 stars$2.90-0.3%$5.00+72.4%+72.3%$162.70M$47.98M-2.27150Positive NewsDMACDiaMedica Therapeutics1.1727 of 5 stars$3.63-3.5%$8.00+120.4%+20.1%$161.24MN/A-5.6720Positive NewsHigh Trading Volume Related Companies and Tools Related Companies Voyager Therapeutics Alternatives Tiziana Life Sciences Alternatives I-Mab Alternatives Lifevantage Alternatives Enanta Pharmaceuticals Alternatives Innate Pharma Alternatives Alpha Cognition Alternatives Journey Medical Alternatives Spero Therapeutics Alternatives DiaMedica Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:ATNM) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Actinium Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Actinium Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ATNM Stock Alerts